+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Combined lipid-lowering therapy



Combined lipid-lowering therapy



Vnitrni Lekarstvi 64(12): 1177-1184



Dyslipidemia belongs to the main risk factors for atherosclerosis. To achieve current blood lipid targets, it is often necessary to use intensive hypolipidemic therapy including a combination of individual hypolipidemic drugs. In terms of cardiovascular risk reduction, it is important that the patient is treated with the highest tolerated dose of statin. In the next step, we decide to co-administer ezetimibe and/or fibrate, and for high-risk patients an additional treatment with proprotein convertase subtilisin kexin 9 inhibitors should be considered. The manuscript provides an overview of the individual combinations effectiveness to influence lipid spectrum and the incidence of cardiovascular diseases. Key words: cardiovascular disease - dyslipidemia - ezetimibe - fibrates - PCSK9 inhibitors - statins.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 066446369

Download citation: RISBibTeXText

PMID: 30704254


Related references

Lipid lowering therapy for primary prevention of coronary heart disease--contra lipid lowering therapy. Zeitschrift für Kardiologie 87 Suppl 2: 210-213, 1998

Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. Journal of the American College of Cardiology 54(25): 2358-2362, 2010

Lipid lowering therapy for primary prevention of coronary heart disease--pro lipid lowering therapy. Zeitschrift für Kardiologie 87 Suppl 2: 205-209, 1998

Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation 113(24): 2826-2834, 2006

Determinants of Arterial Wall Remodeling During Lipid-Lowering Therapy: Serial Intravascular Ultrasound Observations From the Reversal of Atherosclerosis With Aggressive Lipid Lowering Therapy (REVERSAL) Trial. Yearbook of Vascular Surgery 2008: 1-2, 2008

Combined antihypertensive and lipid-lowering therapy in experimental glomerulonephritis. Hypertension 23(1): 92-95, 1994

Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation 112(4): 563-571, 2005

Comparative Effects of Diet-Induced Lipid Lowering Versus Lipid Lowering Along With Apo A-I Milano Gene Therapy on Regression of Atherosclerosis. Journal of Cardiovascular Pharmacology and Therapeutics 21(3): 320-328, 2017

Combined lipid lowering drug therapy for the effective treatment of hypercholesterolaemia. European Heart Journal 24(8): 685-689, 2003

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy. Drugs in Context 6: 212511, 2017

Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. Journal of Managed Care Pharmacy 10(5): 404-411, 2004

Therapeutic efficacy of the lipid-lowering armamentarium: The clinical benefits of aggressive lipid-lowering therapy. American Journal of Medicine 104(2 PART A): 9S-13S, 1998

Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. American Heart Journal 141(5): 722-726, 2001

Lipid lowering therapy increases heart rate variability in subjects with combined hyperlipidemia. Journal of the American College of Cardiology 37(2 Supplement A): 221A, February, 2001

Mechanism of action of combined lipid lowering therapy in established coronary artery disease. Circulation 86(4 SUPPL 1): I159, 1992